- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02696070
Nociceptive Pain Fiber Response
January 10, 2018 updated by: Regenesis Biomedical, Inc.
A Multi-Center, Randomized, Sham-Controlled, Double-Blind Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Small Fiber Nerve Growth and Function in Subjects With Painful Peripheral Diabetic Neuropathy
This study is designed to evaluate the effectiveness of the Provant Therapy System in improving localized nerve growth and skin perfusion in subjects with painful peripheral diabetic neuropathy of the foot.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is multi-site, randomized, double-blind, sham-controlled study of the safety and efficacy of multi-dose Provant therapy to evaluate neuronal and vascular response in the treatment of subjects with painful peripheral diabetic neuropathy.
Subjects will be randomized in a 2:1 ratio to receive therapy with an active device or an identical inactive sham device.
Subjects will treat at home twice daily for 60 days after which they will return to the clinic for final evaluations.
Subjects will be evaluated at the research center for a Baseline/Enrollment visit and again at Day 61 where assessments for safety, concomitant medications, Sympathetic Skin Response (SSR), Nerve Conduction Velocity (NCV), Skin Perfusion Pressures (SPP), and Skin Biopsy will be completed.
Subjects will be contacted via telephone at Day 14, Day 28 and Day 42 to assess adherence, safety, and concomitant medications.
Subjects will also complete a Response to Study Device form which will capture their daily pain score.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Extremity Health Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject age is greater than or equal to 22 years and less than 80 years of age.
- Subject has documented Type 2 diabetes.
- Subject has an HgbA1c > 7% and < 10%.
- Subject has peripheral diabetic neuropathy with pain, numbness, tingling, and/or burning in at least one foot confirmed by a positive provocative sign and a positive Tinel's sign. If both feet are involved, the one with the greatest severity will be selected as the index foot.
- Subject is in pain Phase 2, 3, or 4 (Appendix C).
- Subject is willing and able to give written informed consent and to comply with all parts of the study protocol including diary entries.
- Female subjects must be post-menopausal, surgically sterile, abstinent, or practicing (or agree to practice) an effective method of birth control if they are sexually active for the duration of the study. (Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization).
Exclusion Criteria:
- Subject has Type 1 diabetes.
- Subject is in pain Phase 1 or 5 (Appendix C).
- Subject has an active, open ulcer on either lower extremity of arterial, venous or mixed disease origin.
Subject has peripheral arterial disease as determined by an Ankle-Brachial Index (ABI) of >1.40 or < 0.80. See Appendix E for details on obtaining the ABI.
NOTE: If the difference in the brachial pulse pressure between the right and left arms is > 10 mmHg, the subject will not be eligible for enrollment and will be referred to a cardiologist for further evaluation.
- Subject has venous insufficiency classified by the Venous Insufficiency Classification System (CEAP) of grades C3, C4, C5, or C6. See Appendix F for description of the venous insufficiency grading.
- Subject has undergone decompression surgery on the index foot to treat peripheral neuropathy within 2 years of the Screening Visit.
- Subject requires or anticipates the need for surgery of any type during the 60 day treatment period.
- Subject is a smoker or has been a smoker within one year of the Screening Visit.
- Subject has a total foot thickness (plantar surface to mid-dorsal surface) of > 6 centimeters.
- Subject anticipates travelling over the course of the 60 day treatment period.
- Subject has received any investigational drug or device within 30 days or 5 half-lives of the drug, whichever is longer, prior to the Screening Visit or is enrolled in another clinical trial.
- Subject has undergone any local injection into the index foot within 30 days prior to the Screening Visit or within 6 weeks prior to the Screening Visit for long acting lidocaine injection products.
- Subject has used systemic corticosteroids within 2 months of the Screening Visit.
- Subject has a history of any uncontrolled medical illness that in the investigator's judgment places the subject at unacceptable risk for receipt of PEMF therapy.
- Subject has a history of malignancy within the past five years other than successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin in the treatment area and/or localized in situ carcinoma of the cervix.
- Subject has a serious psychosocial co-morbidity.
- Subject has a history of drug or alcohol abuse, as confirmed by urine drug screen, within one year prior to the Screening Visit.
- Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s).
- Subject is currently pregnant or planning on becoming pregnant prior to Day 60.
- Subject has been previously treated with the PROVANT Therapy System.
- Subject is unwilling or unable to follow study instructions, or comply with the treatment regimen and study visits.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Sham of Provant
|
|
OTHER: Active Treatment
Active Provant Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60
Time Frame: 60 days
|
The mean percent change in intraepidermal nerve fiber density mean values for mean nerve fibers per millimeter squared from baseline to Day 60 was calculated for each treatment group (value at 60 days minus value at baseline).
|
60 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (ACTUAL)
December 1, 2016
Study Completion (ACTUAL)
December 1, 2016
Study Registration Dates
First Submitted
February 17, 2016
First Submitted That Met QC Criteria
March 1, 2016
First Posted (ESTIMATE)
March 2, 2016
Study Record Updates
Last Update Posted (ACTUAL)
January 12, 2018
Last Update Submitted That Met QC Criteria
January 10, 2018
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RBI.2015.002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Painful Peripheral Diabetic Neuropathy
-
WinSanTor, IncCompletedPeripheral Neuropathy | Painful Diabetic Neuropathy | Diabetic Neuropathies, PainfulCanada
-
University of PlymouthNot yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
Regenacy Pharmaceuticals LLCCompletedPainful Diabetic Peripheral NeuropathyUnited States
-
Glenmark Pharmaceuticals Ltd. IndiaGlenmark Pharmaceuticals S.A.CompletedPainful Diabetic Peripheral NeuropathyIndia, Czech Republic, Germany, United Kingdom
-
Mitsubishi Tanabe Pharma CorporationCompletedPainful Diabetic Peripheral NeuropathyJapan
-
Astellas Pharma Global Development, Inc.TerminatedPainful Diabetic Peripheral Neuropathy (PDPN)United States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPainful Diabetic Peripheral NeuropathyUnited States, Czechia, Sweden, Italy
-
Astellas Pharma IncCompletedPainful Diabetic Peripheral Neuropathy (PDPN)Belgium, Czech Republic, France, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
-
Helixmith Co., Ltd.CompletedDiabetic Neuropathy, Painful | Painful Diabetic NeuropathyUnited States
Clinical Trials on Provant Therapy System
-
Regenesis Biomedical, Inc.CompletedDiabetic Neuropathy PeripheralUnited States
-
Regenesis Biomedical, Inc.CompletedDiabetic Peripheral NeuropathyUnited States
-
Southern California Institute for Research and...Regenesis Biomedical, Inc.Unknown
-
Regenesis Biomedical, Inc.CompletedOsteoarthritis, KneeUnited States
-
Regenesis Biomedical, Inc.Completed
-
Regenesis Biomedical, Inc.WithdrawnPostoperative PainUnited States
-
Regenesis Biomedical, Inc.CompletedPost-Operative Pain Following Total Knee ArthroplastyUnited States
-
Regenesis Biomedical, Inc.TerminatedDiabetic Foot UlcersUnited States
-
Regenesis Biomedical, Inc.Terminated
-
Regenesis Biomedical, Inc.Completed